Metastatic Urothelial Carcinoma
Conditions
Keywords
bicalutamide, avelumab
Brief summary
This is a Phase II, multi-center, placebo-controlled randomized controlled trial of standard of care (SOC) avelumab versus SOC avelumab with bicalutamide for patients with metastatic or locally advanced urothelial carcinoma.
Detailed description
Urothelial carcinoma (UC) is the second most common urological cancer after prostate cancer. Non-muscle invasive bladder cancer (NMIBC) is the most common form (\ 75%). Muscle-invasive bladder cancer (MIBC) is found at presentation in \ 25% of patients, with 10-20% of NMIBC eventually becoming MIBC. Risk groups for NMIBC are based on number of tumours, stage and size. Almost half of patients with MIBC eventually progress to metastatic disease. Treatments for metastatic urothelial carcinoma (mUC) have evolved rapidly over the last several years. Pembrolizumab demonstrated benefit as second line therapy for locally advanced and metastatic UC. Subsequently, the landmark Phase III randomized JAVELIN trial showed that the addition of avelumab as maintenance therapy following a response to chemotherapy for mUC significantly prolonged overall survival relative to best supportive care (hazard ratio (HR) = 0.69; 95% confidence interval (CI), 0.56-0.86; P = 0.001). Overall survival and progression-free survival were 21.4 months (18.9 to 26.1) and 5.5 (4.2 to 7.2) months, respectively. This trial established avelumab as the SOC treatment and initial immunotherapy for mUC following chemotherapy. The investigators have selected a double-blind placebo-controlled randomized study design to be able to assess the pragmatic endpoint of investigator-assessed clinical progression. Randomization will assign patients 2:1 to bicalutamide 150mg daily plus SOC avelumab or placebo plus SOC avelumab. Patients will be followed every 3 months after avelumab treatment has started and until progression.
Interventions
DRUGPlacebo
placebo
nonsteroidal antiandrogen
Sponsors
Cancer Research Society
CHU de Quebec-Universite Laval
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age 18 or greater and able to provide informed consent for the trial; 2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 at screening; 3. Patients with histologically confirmed urothelial carcinoma; 4. Patients is a candidate for a course of maintenance avelumab treatment for metastatic or locally advanced urothelial carcinoma; 5. Male patients with partners of child-bearing potential must agree to 2 acceptable forms of birth control and be continued for at least 130 days after study drug is discontinued.
Exclusion criteria
1. Patients with a history of liver disease whose hepatic enzymes, alkaline phosphatase or bilirubin are greater than twice the upper limit of normal will be ineligible. 2. Patients with neutrophils (\< 1,000/μL) will be ineligible. 3. Patients on androgen replacement therapy, or those with prostate cancer or other diseases currently treated with systemic hormonal therapy will be ineligible for study enrollment. Patients receiving 5-alpha reductase inhibitors will not be excluded. 4. Patients who have a concurrent malignancy other than UC within the past years for which treatment is planned within the next 6 months. 5. Patients taking an investigational drug within 2 weeks of enrollment into this study. 6. Patients receiving or planning to receive coumadin therapy. 7. Female patients with childbearing potential are excluded due to known teratogenic effects of bicalutamide.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of bladder tumor recurrence | 30 months | The primary outcome will be to the time to investigator-assessed progression on avelumab therapy. |
Countries
Canada
Outcome results
None listed